Adjuvant treatment for high risk HR+ breast cancer | ESMO 2023 Breast Cancer Highlights

Highlights from ESMO 2023 in Breast Cancer – Keynote 756, TROPION-Breast01, Keynote 52Подробнее

ESMO 2020 Expert Video Report on CDK4 6i in the adjuvant treatment of breast cancerПодробнее

ESMO 2023 Breast Cancer Highlights – Keynote 756, TROPION-Breast01, Keynote 52 | Onc BrothersПодробнее

How to sequence ADCs in breast cancer? | ESMO 2023 Breast Cancer HighlightsПодробнее

ASCO 2023 Expert Report in HR positive, HER2 negative breast cancer by Catherine Harper-WynneПодробнее

Identifying High-Risk Individuals for Breast Cancer: Insights from Dr. Huma Noor at Fortis EscortsПодробнее

Adjuvant Therapy | 2023 Best of Breast ConferenceПодробнее

Standard of care practice in Adjuvant HR+ Breast Cancer before ASCO 2023 #oncology #ASCO2023 #cancerПодробнее

Breast cancer at ESMO 2023: ADCs and MONARCH 3Подробнее

ESMO Breast 2021 highlightsПодробнее

Lung cancer highlights from ESMO 2022Подробнее

Treatment options for high risk early breast cancerПодробнее

MonarchE: investigating adjuvant abemacicilib for high-risk HR+ breast cancerПодробнее

#ESMO22 Highlights on abemaciclib + NSAI in HR+/HER2- advanced breast cancer: The MONARCH 3 studyПодробнее

Unanswered questions in the use of adjuvant therapy in early breast cancerПодробнее

Breast cancer research at ESMO 2021Подробнее

Optimizing adjuvant treatment in HR+/HER2- early breast cancerПодробнее

ESMO 2022: Breast cancer highlightsПодробнее

Highlights from ESMO Breast Cancer 2022Подробнее